Actinium Pharmaceuticals, Inc. (NYSE: ATNM) Starts Presentation at 29th Annual ROTH Conference
Actinium Pharmaceuticals (NYSE: ATNM) is a biopharmaceutical company developing innovative targeted payload immunotherapies for the treatment of advanced cancers. The company’s radio-immunotherapy product candidates are based on the combination of the cancer targeting precision of monoclonal antibodies (mAb) that seek out specific types of cells combined with the cytotoxic killing power of radioisotopes that unleash their energy once they have reached their target. For more information, visit the company’s website at www.actiniumpharma.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company…







